Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-1335

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor ; volume:147 ; number:10 ; day:22 ; month:6 ; year:2021 ; pages:2955-2968 ; date:10.2021
Journal of cancer research and clinical oncology ; 147, Heft 10 (22.6.2021), 2955-2968, 10.2021

Creator: Prawira, Aldo
Le, Thi Bich Uyen
Ho, Rebecca Zhi Wen
Huynh, Hung

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00432-021-03703-6

URN: urn:nbn:de:101:1-2021111222435539455693

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Prawira, Aldo
Le, Thi Bich Uyen
Ho, Rebecca Zhi Wen
Huynh, Hung
SpringerLink (Online service)

Other Objects (12)

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma

Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Transient upregulation of IRF1 during exit from naive pluripotency confers viral protection

TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2

Related objects

Reset password